Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancers

Liver Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Graft-Vs-Host Disease

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematology

Lung Cancer

Pediatric Cancer

Sarcomas

Melanoma

Skin Cancer

An LED-based intraoral device for photobiomodulation therapy was safe and reduced severe oral mucositis in patients with head and neck cancers.

Intraoral Photobiomodulation Device Safe, Reduces Oral Mucositis in HNC

Off-the-shelf mosunetuzumab/polatuzumab vedotin produced durable responses with manageable safety in BTK inhibitor–exposed relapsed/refractory MCL.

Fixed-Duration Mosunetuzumab/Polatuzumab Active in R/R MCL

Zidesamtinib, a brain-penetrant, TRK-sparing ROS1 TKI, showed activity and manageable safety in pretreated patients with advanced ROS1+ NSCLC.

Zidesamtinib Active, Safe in Pretreated ROS1+ Advanced NSCLC

Mosunetuzumab plus polatuzumab vedotin increased PFS and response rates vs R-GemOx in transplant-ineligible large B-cell lymphoma.

Mosunetuzumab/Polatuzumab Vedotin Triples PFS in LBCL

News

Latest News

FDA News

Adverse Event Management

Supportive Care

Disparities in Cancer Care

Drug Safety

Radiation Oncology

Survivorship 

Practice Management

Prevention

Contributors

Media

Expert Connections

Morning Rounds

The Vitals

Podcasts

Videos

Between the Lines

From All Angles

Meeting of the Minds

Training Academy

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Case-Based Digest 

Rx Road Map

Events

Subscribe

Partners

Courtney Moore, APRN, FNP-C, OCN, is a nurse practitioner at Norton Cancer Institute Medical Oncology.

Bridget Hoyt is the assistant editor for Oncology Nursing News. She earned her BA in communication studies at Rider University with a minor in public relations. She can be reached at 

Courtney Moore, APRN, FNP-C, OCN, discusses planning beyond first-line CDK4/6 inhibitors and supportive care strategies for patients with HR+/HER2– disease.

Managing Precautions and Next Steps After First-Line CDK4/6 Inhibitors

Subcutaneous daratumumab is well tolerated, but ongoing immune monitoring is key to managing infection risk in patients with multiple myeloma.

Monitoring Immune Health With Subcutaneous Daratumumab

Articles

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for 

. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

The REMS program for vandetanib in the treatment of patients with medullary thyroid cancer has been removed by the FDA.

FDA Ends REMS Program for Vandetanib in Medullary Thyroid Cancer

Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient-centered cancer care.

About Us

Editorial Board

Contact Us

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News – Clinical Insights for Cancer Care Nurses

Facebook

LinkedIn

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Nurse Navigation

Quality Improvement

1rem

View

Clinical Adoption and Impact of Subcutaneous Immune Checkpoint Inhibitors in Oncology Practice

Challenges in IV Administration of Immune Checkpoint Inhibitors & Interest in SubQ

Drivers for SubQ Interest in Oncology Practices & Clinics Workflow Changes

Insights

Challenges in IV Administration of Immune Checkpoint Inhibitors & Interest in SubQ

EP: 1.Challenges in IV Administration of Immune Checkpoint Inhibitors & Interest in SubQ

EP: 2.Drivers for SubQ Interest in Oncology Practices & Clinics Workflow Changes

Newsletter

Latest Conference Coverage